A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children’s Oncology Group Phase 1 and Pilot Consortium (ADVL0921)

BACKGROUND: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Mossé, Yael P., Fox, Elizabeth, Teachey, David T., Reid, Joel M., Safgren, Stephanie L., Carol, Hernan, Lock, Richard B, Houghton, Peter J, Smith, Malcolm A, Hall, David, Barkauskas, Donald A, Krailo, Mark, Voss, Stephan D., Berg, Stacey L., Blaney, Susan M., Weigel, Brenda J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6897379/
https://ncbi.nlm.nih.gov/pubmed/30777875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2675
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi